Are you Gabriele Braun?

Claim your profile

Publications (10)8.85 Total impact

  • Gabriele Braun · Klaus Hellmann
    [Show abstract] [Hide abstract]
    ABSTRACT: A randomised field study was conducted to evaluate the effect of Digextra BB on the weight gain in female dairy calves. Starting from the day of birth (day 0) until day 90, animals in group 1 received 10 g of the product each per day as an addition to the milk or milk replacer. The animals in group 2 were feed according to the same regimen but without any addition to the milk. Seventeen animals per group were weighed on days 0, 14, 91 and 182. For all observation periods the mean weight gain in group 1 was significantly higher than in group 2 (P = 0.0258 for day 0 to 91, P = 0.0165 for day 14 to 91 and P = 0.0777 for day 0 to 182). The average daily weight gain in group 1 was significantly higher than in the control group, from day 14 to Tag 91 by 103 g (P = 0.0171) and from day 0 to Tag 182 by 69 g (P = 0.0787). The addition did not have an impact on palatability and it was easy to suspend in milk and milk replacer. Based on the evaluations of this study the addition of Digextra BB to the milk improved the weight gain in rearing dairy calves.
    No preview · Article · Nov 2014 · Tierärztliche Umschau
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Dirofilaria repens is the causative agent of subcutaneous dirofilariosis of dogs, other animals and humans. This nematode is transmitted by mosquitoes of Aedes, Anopheles and Culex genera. In dogs, the parasite may cause subclinical infection or cutaneous signs. Recently, D. repens has emerged and spread in different geographical areas, with an increase of cases in dogs and humans. Chemoprevention in dogs in endemic areas is the most reliable approach for controlling this infection. This paper describes a randomized, blocked and multicentric clinical field study investigating the efficacy of an oral, chewable formulation containing milbemycin oxime/praziquantel (Milbemax®, Novartis Animal Health) in the chemoprevention of subcutaneous dirofilariosis in dogs. Methods This study was conducted in endemic areas of Italy. A total of 249 dogs, at two sites, negative for D. repens, were allocated into two groups (i.e. Treated -T1 vs Untreated-T2) with a ratio of 1:1, and subjected to clinical visits and blood sampling once monthly until the end of the study. All blood samples were microscopically and genetically examined. Animals belonging to T1 group received a minimum target dose of 0.5 mg/kg bodyweight of milbemycin oxime and 5 mg/kg of praziquantel in commercial tablets (Milbemax®) according body weight once every 4 weeks. Animals of group T2 were not treated with Milbemax® but received, when necessary, specific parasiticide treatments. The study duration was 336 ± 2 days for each dog. Results A total of 219 dogs completed the study (i.e. 111 in T1 and 108 in T2), while 30 dogs (i.e. 13 in T1, 17 in T2) were withdrawn for a variety of reasons unrelated to administration of Milbemax®. The percentages of animals not showing microfilariae of D. repens were 100% (111 animals) in T1 and 94.7% (108 animals out of 114) in group T2. Milbemax® was shown to be safe in treated dogs. Conclusions The results of this study confirm that the monthly use of Milbemax® in dogs is effective and safe for the prevention of subcutaneous dirofilariosis in endemic areas.
    Full-text · Article · Jul 2014 · Parasites & Vectors

  • No preview · Conference Paper · Jul 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The nematode Capillaria aerophila (Trichuroidea, Trichuridae) affects the respiratory system of cats and other animals and occasionally of human beings. Infected cats may show bronchovesicular sounds, inflammation, sneezing, wheezing and, chronic cough and, sometimes, bronchopneumonia and respiratory failure. The present study evaluated the efficacy and safety of the antiparasitic spot-on formulation containing imidacloprid 10 %/moxidectin 1 % (Advocate®, Bayer Animal Health) in the treatment of natural feline infection with the lungworm C. aerophila. The efficacy of Advocate® administered once was tested on days 7 ± 1 and 11 ± 1 following treatment at day 0 and compared to faecal egg counts on days -6 ± 1 and -2 ± 1. Overall, 36 cats treated either with Advocate® (treatment group, n = 17 cats) or left untreated (control group, n = 19 cats) were included in the study. Geometric means of faecal egg counts values in eggs per gram of faeces were 124.03 prior to treatment and 0.26 posttreatment in treatment group, while 107.03 and 123.94 pre- and posttreatment in the untreated cats. Post-baseline egg counts showed a 99.79 % reduction in Advocate®-treated animals in comparison with cats which were left untreated. Also, treated cats showed no adverse events. This trial demonstrated that Advocate® spot-on formulation is safe and effective in the treatment of feline lung capillariosis caused by C. aerophila.
    Full-text · Article · Jul 2012 · Parasitology Research
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The objective of this GCP-compliant clinical field study was to evaluate the efficacy of the combination of moxidectin (minimum dose of 2.5 mg/kg body weight) and imidacloprid (minimum dose of 10.0 mg/kg body weight) spot-on (Advocate®) as a preventive and therapeutic treatment of natural infection by Dirofilaria repens in dogs in the Czech Republic. There were two arms of the study, both negatively controlled. 34 animals were randomly allocated to two groups of the treatment arm; 90 negative animals were randomly allocated to the prevention arm groups. All enrolled dogs were observed physically and blood was sampled monthly for Dirofilaria repens microfilaria counts for 18 months by modified Knott test and PCR. 34 dogs were positive for microfilaria and enrolled in the treatment arm of this study (treated: 18, untreated: 16). The reduction of the log-transformed microfilaria counts was significantly higher in the treatment group on day 28 (p = 0.007), 56, 84 and 112 (p < 0.001). All animals treated were negative after a single treatment. In the untreated control group 93.75 % remained positive (p < 0.001). 87 dogs were negative for microfilaria prior to allocation to the “preventive” arm (treated: 49; untreated: 38; 3 excluded). One dog in the untreated control group became positive for Dirofliaria repens microfilaria, while none of the treated dogs became positive. Advocate® was effective in the treatment of dogs infected with microfilaria of Dirofilaria repens. Due to the low rate of natural infections the preventive efficacy could not be proven, but no dog treated became positive.
    Full-text · Article · Aug 2011 · Parasitology Research
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this GCP compliant, randomised and negatively controlled clinical field study the preventive and therapeutic efficacy of Advocate® against natural infection by microfilaria of Dirofilaria repens was evaluated in dogs in the Czech Republic. In the therapeutic arm the reduction of the log transformed microfilaria counts was significantly higher in the Investigational Veterinary Product (IVP) group on day 28 (P=0.007), 56, 84, and 112 (p<0.001). All animals treated with the IVP were negative after a single treatment. In the control group 93.75% of the animals remained positive (P<0.001). In the prevention arm one dog in the untreated control group became positive for Dirofliaria repens microfilaria, while none of the IVP treated dogs became positive. Advocate® was effective in the treatment of dogs infected with microfilaria of Dirofilaria repens. Due to the low rate of natural infections the preventive efficacy was not proven, but no dog treated became positive.
    No preview · Conference Paper · Aug 2011
  • Gabriele Braun · Klaus Hellmann · Erich Reinhart
    [Show abstract] [Hide abstract]
    ABSTRACT: Puerperal septicaemia and toxaemia (MMA) in sows is one of the most common and economically important loss-makers in piglet rearing. Usually MMA is treated with antibiotics together with non-steroidal antiphlogistic agents. In the present study the clinical safety and efficacy of two combined homeopathics were compared to a standard treatment of antibiotics and an optional addition of a non-steroidal antiphlogistic drug. In three German veterinary practices with one piglet rearing farm each, in total 64 sows (1st to 10th farrowing) suffering from MMA were treated for up to 3 days. At enrolment in the study an MMA-sum score, consisting of five single parameters, of ≥ 4 points had to be present. Animals were allocated to one of the two treatment groups according to the provided randomisation list. Each of the 30 sows in the experimental group received subcutaneously at the base of the ear once daily 5 ml of La-chesis compositum N ad us. vet. and 5 ml Traumeel LT ad us. vet. (Biologi-sche Heilmittel Heel GmbH), until cure (defined as reaching an MMA score of ≤ 2), for a maximum of 3 days. 34 animals in the control group were treated intramuscularly according to the manufacturer's instructions with 2.5 mg of Enrofloxacin (Baytril® - Das Original 10% - Injektionsldsung, Bayer Vital GmbH) per kg body weight and day until cure, for a maximum of 2 days. Clinical examinations were carried out once daily either until cure, orfor a maximum of 4 days for the experimental group, andfor a maximum of 3 days for the control group. Additionally the weight gains of the piglets from the first day of therapy to the eighth day p.p. and the numbers of live piglets on the first day of therapy and on the day of weaning were determined. In the experimental group the mean MMA-sum score was reduced from 5.2 (baseline on treatment day 1) via 3.6 and 2.7 to 2.8 (after 3 treatment days). In the control group a reduction from 5.3 (baseline on treatment day 1) via 3.6 to 2.5 (after 2 treatment days) was observed. There was no significant difference between groups on the individual treatment days (p>0.79; 95% CI for treatment days 2 and 3 from-1.10 to 1.01 and -1.35 to 1.03 respectively). The overall rate of cured animals was 71.4% (20 animals) in the experimen-tal group and 65.6% (21 animals) in the control group. The difference in the percentage of cured animals (experimental group-control group) was 5.8 % (95 % CI from -17.7% to 29.3 %) in favour of the experimental group. The loss of piglets was 11.5 % in the experi-mental group and there was no significant difference to the control group (10%, p=0.76). The mean weight gains of piglets until their eighth day of life tended to be higher in the experimental group (1.7 kg) than in the control group (1.5 kg). The results of all examined parameters of the present study show, that the efficacy of the treatment against MMA with Lachesis composi-tum N ad us. vet. in combination with Traumeel LT ad us. vet. is comparable to a conventional treatment with anti-infective drugs such as Enrofloxacin and non-steroidal antiphlogistic agents such as Meloxicam.
    No preview · Article · Jul 2011 · Tierärztliche Umschau
  • [Show abstract] [Hide abstract]
    ABSTRACT: The authors compared the symptomatic effectiveness of a complex homeopathic preparation Zeel (1-3 tablets orally per day depending on body weight) to carprofen (4 mg/kg body weight) in dogs (n=68) aged >1 yr diagnosed with osteoarthritis in a multicenter, prospective, observational open-label cohort study in 12 German veterinary clinics. The active treatment period was 56 days. Symptomatic effectiveness, lameness, stiffness of movements, and pain on palpation were evaluated by treating veterinarians and owners. Clinical signs of osteoarthritis improved significantly (P<0.05) at all time points (days 1, 28, and 56) with both therapies. At the end of the treatment period, effectiveness was comparable in both groups. Both treatment regimens were well tolerated with only three treatment-related adverse events, all in the carprofen group.
    No preview · Article · Jan 2011 · Journal of the American Animal Hospital Association
  • [Show abstract] [Hide abstract]
    ABSTRACT: The therapeutic and metaphylactic efficacy of tulathromycin during a natural outbreak of porcine respiratory disease (PRD) was evaluated in two swine farms (Germany, Slovenia) in a randomised, masked parallel design study. In the therapeutic part (phase 1) tulathromycin was compared to a positive control, in the metaphylactic part (phase 2) to a negative control. Outbreaks were identified when 20 to 30 per cent of animals in the stall were exhibiting clinical signs of PRD. Once an outbreak had been established, the swine with clinical signs of PRD were enrolled in phase 1 and allocated to treatment in a 1:1 ratio by the intramuscular route with a single injection of tulathromycin (n = 61) 2.5 mg/kg or a single injection of amoxicillin/clavulanic acid 7.0/1.75 mg/kg on three consecutive days (n = 62). The healthy incontact pigs were used in phase 2 of the study and were allocated to treatment in a 1:1 ratio by the intramuscular route with a single injection of either tulathromycin (n = 162) 2.5 mg/kg or saline (n = 158). There were no treatment-related adverse experiences. For pigs with PRD (phase I), there were marked clinical improvements and highly significant decreases in pyrexia at both sites during the study for both treatments (P < 0.0001) but no significant differences between treatments (P > 0.05). Significantly greater numbers of tulathromycin-treated pigs compared with saline-treated animals remained clinically unaffected with no clinical signs of PRD by day 21 (Germany: 79.0 % vs 62.0 %, P = 0.022; Slovenia 63.0% vs 39.2 %, P = 0.004). Therapeutic and metaphylactic administration of tulathromycin was found to be safe and efficacious in PRD associated with Haemophilus parasuis during natural outbreaks amongst growing pigs.
    No preview · Article · Nov 2008 · Tierärztliche Umschau

  • No preview · Article ·